TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12390569

Group type: EXPERIMENTAL
Intervention: Orally administered amoxicillin at 500 mg, 3 times daily for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Orally administered metronidazole at 250 mg, 3 times daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP only or SRP followed by 14 days of orally administered doxycycline at 4 micro g/mL
Number of subjects: 20
Study: 9824881

Group type: EXPERIMENTAL
Intervention: Continuous Performance Task (CPT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Span of Apprehension Task (SPAN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symptoms assessment at 12 months
Number of subjects: 40
Study: 7659739

Group type: EXPERIMENTAL
Intervention: Hand-held dynamometer (myometer)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Kin-Com dynamometer
Number of subjects: 10
Study: 2649130

Group type: EXPERIMENTAL
Intervention: Combination treatment (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with triiodothyronine)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sequential single agent therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with vincristine)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sequential single agent therapy
Number of subjects: 222
Study: 7391628

Group type: EXPERIMENTAL
Intervention: A-Group: 900 mg of calcium, 50 mg of sodium fluoride, 50,000 units of vitamin D twice weekly
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: B-Group: 900 mg of calcium, 50 mg of sodium fluoride
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: C-Group: 50 mg of sodium fluoride
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: D-Group: 900 mg of calcium, 50 mg of sodium fluoride, 2 mg of estriol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: E-Group: 2 mg of estriol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: F-Group: 900 mg of calcium
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: G-Group: 900 mg of calcium, 2 mg of estriol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 77
Study: 30395006

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (penetrating needle at right Hegu acupoint LI-4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture (nonpenetrating needle)
Number of subjects: 0
Study: 27928625

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (RT)
Number of subjects: 107
Study: 26721134

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment (14 sessions, based on Zusanli, Yinlingquan, Zhongwan, Danzhong, Neiguan, Taichong, Ganshu, Geshu, Danshu)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Chinese herbs, one dose a day for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Chinese herbs)
Number of subjects: 80
Study: 22405557

Group type: EXPERIMENTAL
Intervention: One-dose-adjuvanted primary administration followed by a single-adjuvanted booster dose containing a heterologous vaccine strain
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Increasing the interval between the first and second dose (from 21 days to 12 months)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: HI antibody response against the two strains
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Neutralizing antibody responses and CMI
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Overall vaccine
Number of subjects: 512
Study: 21236421

Group type: EXPERIMENTAL
Intervention: In vitro maturation treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: Infertile control group
Number of subjects: 128
Study: 19326598

Group type: EXPERIMENTAL
Intervention: Slow ascent protocol (15 days to summit)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fast ascent protocol (19 days to summit)
Number of subjects: 34
Study: 17765775

Group type: EXPERIMENTAL
Intervention: Floseal (FS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 68
Study: 16311300

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 50

Group type: COMPARATOR
Intervention: DMPA alone
Number of subjects: 50
Study: 14576538

Group type: EXPERIMENTAL
Intervention: 0% nitrous oxide with 1.2, 1.4, 1.6, 1.8, or 2.0% sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 33% nitrous oxide with 0.8, 1.0, 1.2, 1.4, or 1.6% sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 67% nitrous oxide with 0.4, 0.6, 0.8, 1.0, or 1.2% sevoflurane
Number of subjects: 120
Study: 10473995

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 830

Group type: COMPARATOR
Intervention: Alfuzosin 2.5 mg three times daily
Number of subjects: 830

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 830
Study: 8835055

Group type: EXPERIMENTAL
Intervention: Elemental zinc supplementation in daily dosages of 25‐100 mg po
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc supplementation
Number of subjects: 0
Study: 1745854

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 0.2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 1.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral salbutamol 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral salbutamol 8 mg
Number of subjects: 12
Study: 7049385

Group type: EXPERIMENTAL
Intervention: Standard-dose CMF
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-dose CMF
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall CMF (both doses)
Number of subjects: 52
Study: 29649341

Group type: EXPERIMENTAL
Intervention: BioFlo® PICC (AngioDynamics Inc, Queensbury, NY)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (polyurethane PICC with a clamp)
Number of subjects: 150
Study: 27100859

Group type: EXPERIMENTAL
Intervention: One-time brief lifestyle consultation with a nurse (1 hour) and a nutritionist (1 hour) providing personalized lifestyle recommendations based on national guidelines.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group receiving the National Cancer Institute publication, 'Facing Forward: Life after Cancer Treatment.'
Number of subjects: 126
Study: 25331236

Group type: EXPERIMENTAL
Intervention: 1-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Number of subjects: 87

Group type: COMPARATOR
Intervention: 5-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Number of subjects: 87
Study: 22535748

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25
Study: 20685495

Group type: EXPERIMENTAL
Intervention: OLM/AZL 20/16 mg
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: OLM/AZL 10/8 mg
Number of subjects: 862

Group type: COMPARATOR
Intervention: OLM
Number of subjects: 862

Group type: COMPARATOR
Intervention: AZL
Number of subjects: 862
Study: 18164463

Group type: EXPERIMENTAL
Intervention: Minimally invasive nuclear decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical therapies
Number of subjects: 0
Study: 16503317

Group type: EXPERIMENTAL
Intervention: EZE + statin
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Placebo + statin
Number of subjects: 1307
Study: 12094185

Group type: EXPERIMENTAL
Intervention: High diuretic doses
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Use of metolazone
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Low angiotensin-converting enzyme inhibitor dose
Number of subjects: 1153
Study: 10333344

Group type: EXPERIMENTAL
Intervention: High sodium diet (12-15 g NaCl/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low sodium diet (1-3 g NaCl/day)
Number of subjects: 53
Study: 8618187

Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 1 and 3 months
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 2 and 4 months
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 2 and 6 months
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 4 and 6 months
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Three-dose schedule at 2, 4, and 6 months
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: All schedules
Number of subjects: 196
Study: 1941708

Group type: EXPERIMENTAL
Intervention: Self-administered DIS (S-DISSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interviewer-administered DIS (I-DISSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional interviewer-administered DIS (T-DIS)
Number of subjects: 0
Study: 7102384

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31483891

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus
Number of subjects: 75

Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 75
Study: 29629619

Group type: EXPERIMENTAL
Intervention: Ezetimibe (oral formulations)
Number of subjects: 28
Study: 28623823

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200mg twice daily
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 25855851

Group type: EXPERIMENTAL
Intervention: Topical platelet derived growth factor (Regranex)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23339536

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Brief Supportive Psychotherapy (BSP)
Number of subjects: 395
Study: 21226820

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 36
Study: 20205019

Group type: EXPERIMENTAL
Intervention: Incentive condition (n = 80)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control condition (n = 86)
Number of subjects: 166
Study: 16824248

Group type: EXPERIMENTAL
Intervention: propofol medium‐chain triglyceride/long‐chain triglyceride + lidocaine
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: propofol long‐chain triglyceride + lidocaine
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: propofol medium‐chain triglyceride/long‐chain triglyceride
Number of subjects: 464

Group type: COMPARATOR
Intervention: propofol long‐chain triglyceride
Number of subjects: 464
Study: 12959823

Group type: EXPERIMENTAL
Intervention: Community-based (CB) recruitment strategies
Number of subjects: 833

Group type: COMPARATOR
Intervention: Clinic centre site-visit (CSV) recruitment
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Community-based (CB) recruitment
Number of subjects: 833
Study: 10636276

Group type: EXPERIMENTAL
Intervention: Inoue technique
Number of subjects: 302

Group type: COMPARATOR
Intervention: double-balloon technique
Number of subjects: 302
Study: 8956632

Group type: EXPERIMENTAL
Intervention: Topical timolol (0.5%)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical latanoprost (0.005%)
Number of subjects: 15
Study: 1578922

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX (Regimen A)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus asparaginase (Regimen B)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given early (Regimen C)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given over the first 16 months of therapy (Regimen D)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Overall treatment approach for ALL
Number of subjects: 2404
Study: 3001778

Group type: EXPERIMENTAL
Intervention: 200 mg suloctidil 3-times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30771333

Group type: COMPARATOR
Intervention: Monthly dosing of ranibizumab 0.3 mg every 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treat and extend without laser (TREX)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treat and extend with navigated laser (GILA)
Number of subjects: 150
Study: 28841772

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) diet
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-Fat (LF) diet
Number of subjects: 107
Study: 25577772

Group type: EXPERIMENTAL
Intervention: Composite score of echocardiographic indices (derived from LV mass, LA volume, E:e', and s')
Number of subjects: 849
Study: 23337366

Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF)
Number of subjects: 708

Group type: COMPARATOR
Intervention: ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF (ATV/RTV + FTC/TDF)
Number of subjects: 708
Study: 21651419

Group type: EXPERIMENTAL
Intervention: Web-based intervention program (quit the shit), 50-day intervention
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Web-based intervention program (quit the shit)
Number of subjects: 1292
Study: 20088416

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine (Luminal 30 mg thrice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chinese medicine (herbal decoction)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture, Western medicine, Chinese medicine
Number of subjects: 90
Study: 17955107

Group type: EXPERIMENTAL
Intervention: sumatriptan/naproxen sodium (85 mg sumatriptan and 500 mg naproxen sodium)
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: sumatriptan
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 2
Study: 15491092

Group type: EXPERIMENTAL
Intervention: Folic acid (5mg/day) with oral hygiene measures (group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral hygiene measures alone (group I)
Number of subjects: 60
Study: 15001028

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral body image intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief educational session (control group)
Number of subjects: 0
Study: 9860069

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) at doses of 75 or 150 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 26
Study: 7634504

Group type: COMPARATOR
Intervention: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) for 6 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Growth hormone replacement for 12 months
Number of subjects: 22
Study: 2571434

Group type: EXPERIMENTAL
Intervention: Beta-blockers (metoprolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretics (thiazide based)
Number of subjects: 0
Study: 582628

Group type: EXPERIMENTAL
Intervention: Oral local anaesthetic (oxethazaine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alkali (aluminium hydroxide and magnesium hydroxide)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of local anaesthetic and alkali (Mucaine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 31432928

Group type: EXPERIMENTAL
Intervention: CWA, OWA, UWA
Number of subjects: 19

Group type: COMPARATOR
Intervention: CT
Number of subjects: 19
Study: 28790224

Group type: EXPERIMENTAL
Intervention: Glucosamine-Chondroitin Sulfate (GC)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Glucosamine-Chondroitin Sulfate-Methylsulfonylmethane (GCM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 26343717

Group type: EXPERIMENTAL
Intervention: Fish oil-containing emulsion (FO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soybean oil emulsion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 23835687

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg·min(‐1)) + GIP (2 pmol/kg·min(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: GLP-1 (1.2 pmol/kg·min(‐1)) + 0.9% saline (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GIP (2 pmol/kg·min(‐1))
Number of subjects: 20
Study: 21636134

Group type: EXPERIMENTAL
Intervention: Olanzapine (n=28)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Risperidone (n=21)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 18614241

Group type: EXPERIMENTAL
Intervention: PHQ-9
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: EPDS
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SRQ-20
Number of subjects: 160
Study: 16759395

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique using the Mayo vein stripper (Group B)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional open technique (Group A)
Number of subjects: 77
Study: 12525193

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiation therapy (arm 1)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiation therapy (arm 2)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Radiation therapy alone (arm 3)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Overall (all arms)
Number of subjects: 517
Study: 10229297

Group type: EXPERIMENTAL
Intervention: Type 2 DM patients
Number of subjects: 20
Study: 8751270

Group type: EXPERIMENTAL
Intervention: Oral administration of metronidazole (MTN), 500 mg twice a day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2% clindamycin (CLDM) phosphate in a vaginal cream, 5 g once a day for 7 days
Number of subjects: 100
Study: 1882058

Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride solution
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (deionized water)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (after placebo treatment)
Number of subjects: 95
Study: 6979475

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (dose ratio 3:2) for 14 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cotrimole (dose ratio 3:2) for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cotrimole
Number of subjects: 28
Study: 3892794

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) plus Antilymphocyte globulin (ALG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methylprednisolone (MP) alone
Number of subjects: 54
Study: 31446149

Group type: COMPARATOR
Intervention: Online Adaptive Replanning (OLAR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Repositioning
Number of subjects: 21
Study: 29683538

Group type: EXPERIMENTAL
Intervention: viable cryopreserved placental membrane (vCPM)
Number of subjects: 360

Group type: COMPARATOR
Intervention: good wound care
Number of subjects: 360
Study: 26297851

Group type: EXPERIMENTAL
Intervention: Verbal communication with black patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nonverbal communication with black patients
Number of subjects: 33
Study: 25585479

Group type: EXPERIMENTAL
Intervention: Horticultural therapy intervention (HT intervention) for 16 weeks, comprising 16 weekly sessions (120 min each) at the community center and 15 minutes per day at participants' homes.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Horticultural therapy intervention (HT intervention) for 16 weeks.
Number of subjects: 45
Study: 22569966

Group type: EXPERIMENTAL
Intervention: Electrode location at 31 mm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Electrode location at 12.6 mm (mid-region stimulation)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Electrode locations with different lengths (31, 23.8, 16.6 mm)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Electrode locations with different lengths (12.6 mm)
Number of subjects: 7
Study: 20706740

Group type: EXPERIMENTAL
Intervention: TENS therapy with HAN stimulation (TENStem eco), 30 min at least two times a day for 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TENS therapy with HAN stimulation (TENStem eco)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study: 18545115

Group type: EXPERIMENTAL
Intervention: Transtendinous nailing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paratendinous nailing
Number of subjects: 50
Study: 15780457

Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task with random number generation secondary task (executive resource loading)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iowa Gambling Task with no secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task with a secondary task that does not load executive function
Number of subjects: 0
Study: 12888137

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10232294

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids (9.6 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 30
Study: 8911127

Group type: EXPERIMENTAL
Intervention: Psychological intervention (weekly cognitive individual psychotherapy and bimonthly family counselling)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard follow-up (Control)
Number of subjects: 36
Study: 2060557

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6218583

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clindamycin and aminoglycoside combination
Number of subjects: 60
Study: 30563776

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day for 6 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 29494953

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27